MedTrace Logo

Thromboelastographic Methods in Deciding Therapy on Moderate to Severe COVID-19 Patients

NCT05343728 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-04-25

No results posted yet for this study

Summary

This study is a prospective observational study that compares the anticoagulant therapy decision time among moderate and severe COVID-19 patients whose coagulation profiles were tested with thromboelastography (TEG) to those with a standard coagulation profile laboratory examination.

Conditions

Interventions

DIAGNOSTIC_TEST

Thromboelastography

Thromboelastography was done by using TEG 5000 Hemostasis Analyzer (Haemonetics Corp., USA)

DIAGNOSTIC_TEST

Standard coagulation profile laboratory examination

Standard coagulation profile laboratory examination (platelets, PT/APTT, fibrinogen, and D-dimer) was performed by using Sysmex® CS-2500 and 5100 (Sysmex Corp., Japan)

Sponsors & Collaborators

  • Indonesia University

    lead OTHER

Principal Investigators

  • Andi Ade Wijaya Ramlan, MD, PhD · Indonesia University

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-03-01
Completion
2021-07-09

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05343728 on ClinicalTrials.gov